Pliant Therapeutics

Pliant Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops novel oral therapies for fibrosis and other serious diseases. Its work centers on integrin biology. Its lead candidate is bexotegrast (PLN-74809), a dual αvβ6/αvβ1 integrin inhibitor that was studied in idiopathic pulmonary fibrosis and primary sclerosing cholangitis. Its mission is to bring transformative treatments to patients with limited options.